Back to top
more

Edwards Lifesciences (EW)

(Real Time Quote from BATS)

$62.69 USD

62.69
2,229,008

-1.05 (-1.65%)

Updated Jul 30, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Kevin Cook headshot

Bull of the Day: Edwards Lifesciences (EW)

The world leader in non-surgical heart valve replacement keeps the "beat and raise" going with innovation and execution

    Here's Why Investors Should Buy Amedisys (AMED) Right Now

    Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

      Align Technology's Invisalign Sales Strong Amid Margin Woes

      Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.

        LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space

        LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.

          CVS Health (CVS) Releases Encouraging Flu Shot Survey Data

          CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.

            Here's Why Investors Should Buy BioTelemetry (BEAT) Now

            BioTelemetry's (BEAT) buyout of LifeWatch AG has expanded its product portfolio and customer base in the cardiac monitoring and diagnostic services space.

              Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA

              Zacks.com featured highlights: SP Plus Corp, Edwards Lifesciences, Magna International and NVIDIA

                Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

                  Tirthankar Chakraborty headshot

                  4 Stocks to Buy as Q2 Earnings Season Nears Close

                  Earnings growth is considered to be the most significant variable in influencing the share price.

                    Accelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%

                    Accelerate Diagnostics (AXDX) was a big mover last session, as the company saw its shares rise more than 5% on the day.

                      Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

                      Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

                        Allscripts, Elligo Health Enter in Strategic Partnership

                        Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

                          Walgreens' (WBA) Research Website to Add Value in Healthcare

                          Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

                            Omnicell Upgrades Web Portal, Grows in Medication Management

                            Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

                              Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

                              Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

                                Here's Why Investors Should Buy Edwards Lifesciences Now

                                Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

                                  Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                                  IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

                                    Is Edwards Lifesciences Corporation (EW) a Great Growth Stock?

                                    Edwards Lifesciences Corporation (EW) is a company that might be well-positioned for future earnings growth.

                                      Here's Why Investors Should Buy Align Technology (ALGN) Now

                                      Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.

                                        Abbott-North West London Pathology Expand in Diagnostics

                                        Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

                                          Intuitive Surgical at 52-Week High: What's Driving the Stock?

                                          Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.

                                            Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study

                                            Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.

                                              Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

                                              Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.

                                                Varian (VAR) Rides on Oncology and Proton Therapy Businesses

                                                Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.

                                                  Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss

                                                  Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.